Damage control, soins prolongés à l'avant: Rien de neuf

Nos anciens de la Der des Der l'avaient vécu , y avaient réfléchi avec leurs moyens

 

et on a oublié.

 

 

Clic sur l'image pur accéder au document

Nos anciens (ceux de la "der des der") nous l'avaient dit, mais on a oublié leurs écrits

Un retour en arrière qui vaut le détour. Nombre de nos problématiques existaient déjà pendant la grande guerre

Clic sur l'image pour accéder au document

Point de situation 2026 sur les pansements hémostatiques

A review on hemostatic materials: Past, present and future developments

Xiao YC et Al.  Biomater Adv. 2026 Aug:185:214830. doi: 10.1016/j.bioadv.2026.214830.

------------

Un petit pavé qui fait un point sur les pansements hémostatiques dont on mesure la complexité 

------------

Hemostatic materials are essential to control bleeding, promoting wound healing, and reducing complications across a wide range of medical applications, including surgical procedures, trauma care, and minimally invasive interventions. But commercial hemostatic materials still possess several disadvantages. Therefore, the development of safe, effective, and user-friendly hemostatic materials remains a critical goal. Recent advances led to the development of different hemostatic agents, including inorganic materials (kaolin, silica, and zeolites), biobased polymers (polysaccharides, chitosan, alginate, cellulose, starch, and hyaluronic acid), peptides (short amino acid chains), proteins (fibrin, gelatin, and collagen), synthetic polymers (polyethylene glycol and polyvinyl alcohol), and hybrid systems combining inorganic and organic components. These materials were engineered into a range of functional forms, including nanofibers, gels (aerogels and hydrogels), sponges (foams), dressings (gauzes, films, membranes), powders (nanoparticles), and injectable solutions. This review presents the mechanisms of action, characterization methods, and global market status, as well as the material and morphological classifications of hemostatic materials, along with commercial products and research developments. Recent findings and key challenges are also reviewed, including hemostatic performance metrics (clotting time and blood loss), as well as material properties (biocompatibility, biodegradability, antibacterial activity, and toxicity). Finally, recent innovations and trends are discussed.

-------------

"The next generation of HM should meet the following key performance criteria: 1) Be applicable directly to various types of wounds with rapid clotting time. 2) Be cost-effective, scalable, and batch-consistent. 3) Have extended shelf life, be easy to transport, and require minimal storage conditions. 4) Be completely biodegradable or easily removable without triggering pain or bleeding. 5) Avoid inflammatory degradation by-products. 6) Support cell proliferation, anti-inflammation, and tissue regeneration"